Figure 1 Comparison of OS among AJCC stages. OS, overall survival; AJCC, American Joint Committee on Cancer

Figure 2 Comparison of PFS among AJCC stages. PFS, progression free survival; AJCC, American Joint Committee on Cancer

Figure 3 Comparison of OS (A) and PFS (B) between the treatment methods in stage I-II. OS, overall survival; PFS progression-free survival.

Figure 4 Comparison of OS (A) and PFS between the treatment methods in stage III. OS, overall survival; PFS, progression-free survival.

Figure 5 Comparison of OS (A) and PFS between the treatment methods in stage IV. OS, overall survival; PFS, progression-free survival.

Characteristics Number %
Age(year) 47.94±13.250
Range 1 2-85
Median 48. 00
Male: Female 13 5:48
Histology
WHOType I 20 10.9
WHOType II 41 22.4
WHOType III 122 6.7
Stage(AJCC2010)
StageI 15 8.2
StageII 45 24.6
StageIII 96 52.5
StageIV  27 14.8
T Classification
T1 35 19.1
T2 73 39.9
T3 56 30.6
T4 19 10.4
N Classification
N0 43 23.5
N1 83 45.4
N2 48 26.2
N3 9 4.9
M Classification
M0 178 97.3
M1 5 2.7
Primary Treatment
RT 20 11. 0
NAC+RT+CCRT 14 24. 0
CCRT+RT+AC 119 65. 0

Table 1:AJCC, America Joint Committee on Cancer; RT, Radiotherapy, NAC, Neo-adjuvant Chemotherapy, CCRT, Concurrent Chemotherapy

Univariate analysis of prognostic factors for OS and PFS
Factors n() 5-year OS rate(%) x2 *P value 5year PFS rate(%) x2 *P value
Age-group 103 58.3 5.208 0.022 53.4 4.773 0.029
<50 80 41.3 32.5
50 and above
Gender
Male 135 43.8 4.15 0.042 39.6 4.38 0.036
Female 48 60.3 59.3
Stage (AJCC 2014)
Stage I 15 66.7 9.275 0.026 60. 0 8.103 0.044
Stage I I 45 55.6 51.1
Stage I I I 96 41.8 36.6
Stage IV 27 25.9 18.6
T classification
T1 35 57.1 9.119 0.028 51.4 9.737 0.021
T2 73 54.4 50.7
T3 56 41.4 35.7
T4 19 21.3 15.8
M classification
M0 178 50.6 4.975 0.026 48.3 4.558 0.035
M1 5 0. 00 0. 00
Primary treatment
RT 20 42.1 8.921 0.012 36.8 10.5 0.005
NAC+RT+CCRT 44 50.4 45.5
CCRT+RT+AC 119 69.7 67.2
Treatment Effects
NC 11 9.1 16.567 0.001 0 .0 20.061 0. 000
PD 14 14.4 7.1
PR 34 47.1 41.2
CR 124 56.5 52.4

Table 2: AJCC, America Joint Committee on Cancer; RT, Radiotherapy, NAC, Neo-adjuvant Chemotherapy; AC, Adjuvant Chemotherapy, CCRT, Concurrent Chemotherapy; CR, complete response; PR , partial response; NC, no change; PD, progression disease; OS, overall survival; PFS, progression free survival

Variable Patients Hazard ratio 95% CI *P value Hazard ratio 95% CI *P value
Age group <50 103 1.12 1.41- 3.82 0.043 2.052   1.20-3.05 0.017
50 and above 80
Gender
Male 135 0.35 0.147-0.817 0.01 0.383 0.189-0.776 0.07
Female 48
Histology
WHO Type I 20 2.57 0.841-1.853 0.088 1.408  0.667-2.969  0.368
WHO Type II 41
WHO Type III 122
Stage (AJCC 2010)
Stage I 15 0.748 0.317-1.764 0.034 1.008 0.502-2.025 0.029
Stage II 45
Stage III 96
Stage IV 27
T classification 
T1 35 1.427 0.610-3.337  0.025 1.05  0.54-2.039 0. 000
T2 73
T3 56
T4 19
N classification
N0 43 0.904 0.464-1.758 0.765 1.232 0.622-2.437 0.547
N1 83
N2 48
N2 9
M classification
M0 178 4.278 0.679-26.940 0.019 4.304 0.697-26.576 0.046
M1
Primary treatment
RT 20 2.114 1.123 -3.978  0. 000 0.636 0.322-1.254 0.01 0
NAC+RT+CCRT 44
CCRT+RT+CCRT 119
Treatment Effects
NC  14 1.165 0.611-2.224 0.004 1.364 0.696- 2.674 0.03 0
PD 17
PR 34
CR 118

AJCC, America Joint Committee on Cancer; RT, Radiotherapy, NAC, Neo-adjuvant Chemotherapy, CCRT, Concurrent Chemotherapy; CR, complete response; PR , partial response; NC, no change; PD, progression disease; OS, overall survival; PFS, progression free-survival; CI, confidence interval.

Factors N=183 RT(n=20) NAC+RT+CCRT(n=44) CCRT+RT+AC(n=119) x2 *P value
Age group
Less than 50 103 13 20 65 1.961 0.375
50 and above 80 7 23 54
Gender
Male 135 10 34 91 1.201 0.319
Female 48 7 10 31
Histology
WHO Type I 20 1 5 14 3.374 0.497
WHO Type II 41 7 7 27
WHO Type III 122 12 32 78
Stage(AJCC2010)
Stage I 15 15 2 28 70.487 0. 000
Stage II 45 3 24 30
Stage III 96 1 2 47
Stage IV 27 1 16 14
T classification
T1 35 15 2 28 49.873 0. 000
T2 73 3 17 37
T3 56 1 9 40
T4 19 1 16 14
M classification
M0 178 20 44 119 8.434 0 .004  
M1 5 1 4

Table 4: Characteristics of patients’ different primary treatment modalities

OS rate (%) PFS rate (%)
Variable No. of RT NAC+RT+CCRT CCRT+RT+AC RT NAC+RT+ CCRT C CRT+RT+AC
Patients=183 (n=20) (n=44) (n=119) x2 *P value (n=20) (n=44) (n=119) x2 *P value
Stage(AJCC2010)
Stage I 60 34 58.3 62.7 62.451 0. 00 26.9 43.9 56 61.202 0. 000
Stage II 96 28.6 44.3 58.7 15. 0 36.1 50.2
Stage III 27 0. 0 20. 0 36. 7 0. 0 10. 5 23. 6
T classification
T1 35 28.9 47.54 60 .0 0. 028   0.06 0 25.36 44.32 54.4 0.025 0.067
T2 73 20.9 34.6 47.3 19.6 26 45.7
T3 59 17.1 26.1 45. 0 15.3 17.2 33.6
T4 19 5.26 22.9 44. 4 4.9 12.3 30
N classification
N0 43 39.2 44.4 52.1 0.165 0.059 30.2 38.3 47.8 0.122 0.07 0
N1 83 30.2 38.6 46.9 28.3 23.3 46.5
N2 48 14.5 29.5 44.1 10.4 21.6 22.7
N3 9 8.3 11.1 12.6 1.2 2. 0 7. 6
M classification
M0 178 29.21 54.8 60.6 0.629 0.73 11.7 32.02 46.4 4.957 0.175
M1 5 0 8. 87 10.2 0. 0 1.53 5. 70

Table 5: Five year OS and PFS rates of different stages and treatment modalities